HMPL-306
IDH1/2 Mutant Advanced Cancers
Phase I/IIActive
Key Facts
About HUTCHMED
HUTCHMED's mission is to deliver novel, life-changing medicines to patients worldwide, with a core focus on oncology and immunology. The company has achieved a major milestone with the U.S. and EU approval of fruquintinib for metastatic colorectal cancer, validating its global development capabilities and establishing its first commercial beachhead outside China. Its strategy integrates cost-efficient, high-quality R&D in China with strategic global partnerships and commercial operations to maximize the value of its extensive pipeline. HUTCHMED aims to become a leading global biopharma company by advancing multiple late-stage assets and expanding its commercial portfolio.
View full company profile